PCSK9 and familial hypercholesterolemia: Disrupting its function reduces blood LDL levels and represents a promising therapeutic approach for familial hypercholesterolemia with heterozygous loss-of-function mutations in LDLR or gain-of-function mutations in PCSK9 (refs. 20–22).